Target type: biologicalprocess
The process whose specific outcome is the progression of the sinoatrial (SA) node over time, from its formation to the mature structure. The SA node is part of the cardiac conduction system that controls the timing of heart muscle contraction. It relays electrical signals to the AV node. [GOC:mtg_heart]
The sinoatrial (SA) node, the heart's natural pacemaker, arises from a complex interplay of genetic and environmental factors. Its development is a dynamic process, characterized by a precise choreography of cell lineage specification, migration, differentiation, and functional maturation.
**1. Lineage Specification:**
* **Early Cardiac Progenitors:** The journey begins with the specification of cardiac progenitors from the mesoderm, the middle germ layer. These progenitors express key transcription factors like NKX2.5, GATA4, and TBX5, setting the stage for heart formation.
* **SA Node Progenitor Commitment:** Within the developing heart, a specific subpopulation of cardiac progenitors commits to the SA node fate. This commitment involves the activation of a unique transcriptional program, regulated by factors like TBX3, SHOX2, and Tbx18.
**2. Migration and Positioning:**
* **Migration to the Right Atrium:** Guided by chemoattractant signals and cell-cell interactions, SA node progenitors migrate from their initial location near the inflow tract of the heart tube to their final position in the right atrium.
* **Spatial Organization:** The migration is not random; the progenitors precisely align themselves within the developing right atrium, forming a distinct cluster that will give rise to the functional SA node.
**3. Differentiation and Maturation:**
* **Pacemaker Cell Differentiation:** Once in place, the SA node progenitors undergo differentiation, acquiring the unique characteristics of pacemaker cells. This involves the expression of specific ion channels and proteins, such as HCN4, KCNJ2, and CACNA1G, which are crucial for spontaneous depolarization and the generation of rhythmic electrical impulses.
* **Functional Maturation:** As the SA node matures, its cells establish intricate connections with each other via gap junctions, facilitating rapid and efficient electrical signal transmission. This network ensures synchronized and coordinated heart contractions.
**4. Regulation and Fine-tuning:**
* **Neurotransmitters:** The SA node's function is regulated by a complex interplay of neurotransmitters, including acetylcholine (decreasing heart rate) and norepinephrine (increasing heart rate).
* **Hormones:** Hormones like epinephrine and thyroid hormone also influence SA node activity, modulating heart rate and rhythm.
* **Environmental Factors:** Factors like temperature, oxygen levels, and pH can also affect SA node function.
**5. Dysregulation and Disease:**
* **Congenital Heart Defects:** Abnormalities in SA node development can lead to congenital heart defects, affecting heart rate and rhythm.
* **Acquired Disorders:** Disease conditions like heart failure and aging can impair SA node function, leading to bradycardia (slow heart rate) or other arrhythmias.
Understanding the intricate process of SA node development is essential for comprehending the normal function of the heart and for identifying the underlying causes of heart rhythm disorders.'
"
Protein | Definition | Taxonomy |
---|---|---|
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | A potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 that is encoded in the genome of human. [PRO:CNA, UniProtKB:Q9Y3Q4] | Homo sapiens (human) |
Bone morphogenetic protein 4 | A bone morphogenetic protein 4 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P12644] | Homo sapiens (human) |
Voltage-dependent T-type calcium channel subunit alpha-1G | A voltage-dependent T-type calcium channel subunit alpha-1G that is encoded in the genome of human. [PRO:WCB, UniProtKB:O43497] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
tacrine | tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease. Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. | acridines; aromatic amine | EC 3.1.1.7 (acetylcholinesterase) inhibitor |
nimodipine | nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm. Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure. | 2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester | antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent |
pimozide | pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group. Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) | benzimidazoles; heteroarylpiperidine; organofluorine compound | antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist |
mibefradil | Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE. | tetralins | T-type calcium channel blocker |
zatebradine | benzazepine | ||
vexibinol | sophoraflavanone G : A tetrahydroxyflavanone having a structure of naringenin bearing an additional hydroxyl substituent at position 2' as well as a (2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl (lavandulyl) substituent at position 8'. vexibinol: flavanol from Sophora; structure in first source; RN given refers to (S-(R*,S*))-isomer | (2S)-flavan-4-one; 4'-hydroxyflavanones; tetrahydroxyflavanone | antimalarial; antimicrobial agent; antioxidant; plant metabolite |
ivabradine | ivabradine : A member of the class of benzazepines that is 7,8-dimethoxy-1,3,4,5-tetrahydro-3-benzazepin-2-one in which the amide hydrogen is replaced by a [{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl} group. Used (as its hydrochloride salt) to treat patients with angina who have intolerance to beta blockers and/or heart failure. Ivabradine: A benzazepine derivative and selective HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS inhibitor that lowers the heart rate. It is used in the treatment of CHRONIC STABLE ANGINA in patients unable to take BETA-ADRENERGIC BLOCKERS, and in the treatment of HEART FAILURE. | aromatic ether; benzazepine; carbobicyclic compound; tertiary amino compound | cardiotonic drug |
8-prenylnaringenin | 8-prenylnaringenin: a phytogenic antineoplastic agent; structure in first source sophoraflavanone B : A trihydroxyflavanone that is (S)-naringenin having a prenyl group at position 8. | (2S)-flavan-4-one; 4'-hydroxyflavanones; trihydroxyflavanone | plant metabolite; platelet aggregation inhibitor |
flunarizine | Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. | diarylmethane | |
2-phenoxy-N-[5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,4-oxadiazol-2-yl]acetamide | tetralins | ||
(S)-4',5,7-Trihydroxy-6-prenylflavanone | flavanones | ||
ith 4012 | |||
dorsomorphin | dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling. dorsomorphin: an AMPK inhibitor | aromatic ether; piperidines; pyrazolopyrimidine; pyridines | bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor |
kys 05090 | |||
ldn 193189 | LDN 193189: inhibits bone morphogenetic protein signaling | pyrimidines | |
ulixacaltamide | Z944: a T-type calcium channel antagonist | benzamides; monochlorobenzenes; monofluorobenzenes; piperidines; secondary carboxamide | non-narcotic analgesic; T-type calcium channel blocker |
ml347 | ML347: an ALK2 inhibitor; structure in first source |